SCHEMBL6980480

SCHEMBL6980480

O=c1[nH]c2ccccc2c(=O)n1S(=O)(=O)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CMA1 P23946 1/20 0.57
ALDH1A1 P00352 4/20 0.51
FEN1 P39748 2/20 0.51
CA12 O43570 2/20 0.51
CA9 Q16790 2/20 0.51
ADORA3 P0DMS8 1/20 0.51
ADORA2A P29274 1/20 0.51
ADORA2B P29275 1/20 0.51
ADORA1 P30542 1/20 0.51
RNASEH1 O60930 1/20 0.51
ERCC1 P07992 1/20 0.51
ERCC5 P28715 1/20 0.51
ERCC4 Q92889 1/20 0.51
KDM4E B2RXH2 4/20 0.50
HPGD P15428 3/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CYP1A2 P05177 1/20 0.47
NPEPPS P55786 2/20 0.44
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7467460 0.88 CMA1 (0.75) CMA1ALDH1A1FEN1CA12CA9
SCHEMBL6982044 0.84 CMA1 (0.48) CMA1ALDH1A1FEN1CA12CA9
SCHEMBL7464965 0.83 CMA1 (0.85) CMA1ALDH1A1FEN1CA12CA9
SCHEMBL2597418 0.80 ALDH1A1 (0.59) CMA1ALDH1A1FEN1CA12CA9
SCHEMBL4063446 0.80 CHRM1 (0.50) CMA1ALDH1A1ADORA3ADORA1HPGD
SCHEMBL13508987 0.80 ADORA3 (0.59) ALDH1A1FEN1CA12CA9ADORA3
SCHEMBL3789184 0.79 CMA1 (0.47) CMA1ALDH1A1FEN1CA12CA9
SCHEMBL7462723 0.74 HTR6 (0.49)
SCHEMBL22251594 0.74 ALDH1A1 (0.47) ALDH1A1FEN1CA12CA9ADORA3
SCHEMBL7463672 0.73 CMA1 (1.00) CMA1FEN1CA12CA9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030199530-A1 New compounds derived from quinazoline LES LABORATORIES SERVIER (FR) 2003-10-23 US disclosed
EP-1346992-A1 Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2003-09-24 EP disclosed
EP-0795548-B1 QUINAZOLINE DERIVATIVES AND USE THEREOF SUNTORY LTD (JP) 2002-07-03 EP disclosed
US-5814631-A CHYMASE INHIBITOR, CARDIVASCULAR SUNTORY LIMITED (JP) 1998-09-29 US disclosed
EP-0795548-A1 QUINAZOLINE DERIVATIVES AND USE THEREOF SUNTORY LIMITED (JP) 1997-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199530-A1 New compounds derived from quinazoline NQO2, XDH, DRD1 CMA1 760/4885ALDH1A1 331/4885FEN1 1285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.